Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Perspective
Nature Reviews Drug Discovery 5, 107–114 (1 February 2006) | doi:10.1038/nrd1959
Success in translational research: lessons from the development of bortezomib
Abstract
The high price of many innovative drugs, which is in part due to the considerable expense and risk involved in drug development, underlines the need for more efficient approaches to bring drugs to the market, with more effective translational research in particular identified as an important part of such strategies. Here, the development of the cancer drug bortezomib (Velcade; Millennium Pharmaceuticals) by a biotechnology company — Myogenics/ProScript — started by academics from Harvard University is discussed to dissect the key academia–industry/public sector–private sector interactions that made the development of this drug a success despite many barriers. A model to explain how and why bortezomib was approved in record time is presented, and areas for public-policy initiatives to improve translational research in general are highlighted.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
